Europe

Berlin cityscape
#BioInnovation Institute #Biotech #Cardiometabolic diseases #Drug discovery #Europe

German hubs selected for BII cardiometabolic research initiative

BioInnovation Institute (BII) has selected Munich and Berlin as the locations for its German activities under the CardioMetabolic Bridge (CMB) initiative.   The expansion marks another important milestone in BII’s ambition to build a connected European innovation ecosystem dedicated to accelerating the development of new treatments for cardiometabolic… Read More

#News

#Europe #Investment #Market reporting #Survey

European biopharma investment confidence increasing, c-suite survey reveals

Biopharma dealmaking confidence is strengthening, a new survey has revealed, but access to capital remains the defining challenge.  BIO-Europe’s Biopharma C-Suite Agenda Survey 2026 surveyed 81 senior biopharma executives, including 50 CEOs.  The survey results demonstrate that 75% expect partnering and M&A appetite to increase over the next 12 months,… Read More

#Business & Investment #Editor's Choice #News

Europe
#Europe #Investment #Pharmaceutical industry

Pharma urges leaders to reverse Europe’s declining competitiveness

An open letter from the chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi has urged European governments to create conditions that attract investment in next-generation medicines.  They argue that Europe is losing ground to global competition, with over $600 billion in pharmaceutical investment announced… Read More

#Business & Investment #Editor's Choice #News

Map of Europe
#Europe #iiCON: Infection Innovation Consortium #Infectious diseases

European network established to improve infectious disease response

A pan-European network has been established by iiCON: the Infection Innovation Consortium to help harmonise Europe’s response to infectious disease threats. iiCON secured funding from COST (European Cooperation in Science and Technology) to establish a pan-European COST Action network with over 70 collaborators from 21 countries and international organisations. The… Read More

#Business & Investment #News

Kidney on a chip technology
#Europe #Hansa Biopharma #License agreement #MENA

Hansa closes €115m licensing transaction for Idefirix 

Hansa Biopharma has closed a €115 million licensing transaction with SERB Pharmaceuticals for its kidney transplant drug in Europe and MENA.  Idefirix is a first-in-class treatment that specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies within two to six hours. It is conditionally authorised by the European Commission… Read More

#Business & Investment #News

#Cell therapy #Europe #Investment

Cellares extends funding for cell therapy manufacturing 

Cellares has raised $327 million for its cell therapy infrastructure project.  Cellares, which says it is the first Integrated Development and Manufacturing Organization (IDMO), extended its Series D funding thanks to an additional $50 million investment from Prime Radiant Partners.  The investment is set to support the next phase of Cellares’ global Smart Factory… Read More

#Business & Investment #News

#AstraZeneca #Drug discovery #Europe #European Federation of Pharmaceutical Industries and Associations #FDA #Francis Crick Institute #Hypertension #Lung cancer #Mental health #Tropical disease #University of Dundee #Wellcome Trust

DDW Highlights: 26 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a report showed patients in Europe face barriers to medicine access. Elsewhere,… Read More

#Podcasts

Europe
#Europe #European Federation of Pharmaceutical Industries and Associations #FDA

Patients in Europe face barriers to medicine access 

Patients in Europe are waiting longer to access medicines than patients in the US, a new report warns.  The European Federation of Pharmaceutical Industries and Associations (EFPIA)’s report shows 49% of FDA-approved medicines are not available in Europe, up from 46% in 2019.  Data also indicates 17% of medicines are… Read More

#Editor's Choice #News #Regulatory

#Biotechnology #Europe #Funding #Venture funds

European biotech venture builder Kurma closes €215m fund

Kurma Partners, a European healthcare venture capital firm, has announced the final closing of Biofund IV at €215 million.   The new fund will support the discovery and development of disruptive therapeutic solutions for severe or incurable diseases.   Building on the €160 million Biofund III, this successful fundraise has increased the… Read More

#Business & Investment #News

Great British Pounds, Investment
#BioIndustry Association #Europe #Investment #UK

UK leads European biotech investment, BIA reports 

UK biotech led investment in the European market in the first quarter of 2026, new figures from the BioIndustry Association (BIA) show.  The BIA report shows renewed financing was driven by a rebound in venture capital investment and a broader distribution of funding across companies and stages. … Read More

#News

Scientist in laboratory
#ABPI #Europe #Rare diseases #UK

UK must become leader in rare disease medicine, report says 

The UK should look to become a European leader in rare disease medicine, a new report says.  The report, ‘Investing in Rarity: The Economic and Personal Value of Improving Treatment for Rare Disease’, shows that if the UK became the best-performing European country on… Read More

#News

EU flag
#Biotechnology #Business #Europe #Regulatory

Successfully navigating the EU pharma package without the big pharma overhead

Cem Zorlular, CEO of Er-Kim, explains how biotech can turn the new EU pharma package from challenge to opportunity.  In 2028, when new legislation takes effect, the European pharmaceutical landscape will undergo its most significant transformation in two decades. For biotechs, the new EU pharma package is not just a… Read More

#Business & Investment #Exclusive Content

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK government

DDW Highlights: 3 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere,… Read More

#Podcasts

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK #UK government

This week in Drug Discovery (26 – 30 January) 

News round-up for 26 – 30 January by Bruno Quinney, Content Team at DDW.  This week in DDW, discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere, why is the UK leading Europe’s biotech market? The top stories:    Parkinson’s could be identified in… Read More

#News

UK
#Biotech #Europe #UK #UK government

UK is Europe’s leading biotech market, BIA report shows 

The UK retained its position as Europe’s leading national biotech market in 2025, a new report finds.   The BioIndustry Association’s (BIA) report ‘UK biotech financing 2025’ shows the UK market claimed 30% of all European venture financing.  That comes despite a 13.2% year-on-year drop in venture capital investment, totalling £1.79 billion ($2.45 billion) across 58 deals. … Read More

#Business & Investment #News

European map
#BioInnovation Institute #Denmark #Europe #Life sciences #Novo Nordisk Foundation

Novo Nordisk Foundation pledges €736m for scientific innovation 

The Novo Nordisk Foundation has granted DKK 5.5 billion (€736 million) to the BioInnovation Institute (BII) to support life sciences and scientific innovation in Denmark and Europe.  The funding will enable BII to expand its activities into new strategic areas and geographies, supporting even more entrepreneurs and start-up-companies.   BII has already helped… Read More

#Business & Investment #News